Abstract
High response rate in the phase I/II study of meloxicam in juvenile rheumatoid arthritis.
Ivan Foeldvari, Ruben Burgos-Vargas, Angelika Thon and Dietrich Tuerck
The Journal of Rheumatology May 2002, 29 (5) 1079-1083;
Ivan Foeldvari
Ruben Burgos-Vargas
Angelika Thon
In this issue
High response rate in the phase I/II study of meloxicam in juvenile rheumatoid arthritis.
Ivan Foeldvari, Ruben Burgos-Vargas, Angelika Thon, Dietrich Tuerck
The Journal of Rheumatology May 2002, 29 (5) 1079-1083;